See the DrugPatentWatch profile for Delstrigo
Delstrigo received FDA approval on June 17, 2019. [1]
When did Delstrigo become available?
Following its FDA approval, Delstrigo became available for prescription. Information regarding specific market launch dates is not provided.
What is Delstrigo used for?
Delstrigo is a fixed-dose combination medication used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. It is indicated as a complete regimen for individuals not currently receiving antiretroviral treatment or as a replacement for their current antiretroviral regimen, provided they meet specific criteria. [1]
What are the components of Delstrigo?
Delstrigo combines three antiretroviral drugs:
* Dolutegravir 50 mg
* Lamivudine 300 mg
* Tenofovir disoproxil fumarate 300 mg [1]
What is the drug patent status for Delstrigo?
Information on specific patents and their expiry dates for Delstrigo is available through DrugPatentWatch.com. [2]
How does Delstrigo compare to other HIV medications?
Delstrigo is a single-tablet regimen, offering convenience by combining multiple antiretroviral agents into one pill. This approach aims to simplify treatment adherence for patients. [1] Other HIV treatment options include various single-agent drugs, multi-pill regimens, and other fixed-dose combinations, each with different drug components and prescribing guidelines.
What are the potential side effects of Delstrigo?
Common side effects reported with Delstrigo include diarrhea, nausea, headache, and insomnia. More serious adverse reactions can include hypersensitivity reactions, liver problems, and lactic acidosis. [1]
What clinical studies led to Delstrigo's approval?
The FDA approval of Delstrigo was based on clinical studies demonstrating its efficacy and safety in treating HIV-1 infection. Key studies assessed its use in treatment-naive patients and those switching from existing regimens. [1]
Are there any contraindications for Delstrigo?
Delstrigo should not be used in patients with known severe hypersensitivity to its active components or any excipients. It is also contraindicated in patients with severe renal impairment. [1]
What is the recommended dosage for Delstrigo?
The recommended dosage for Delstrigo is one tablet taken orally once daily. [1]
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211903s000lbl.pdf
[2] https://www.drugpatentwatch.com/